Group items tagged

The International Pharmaceutical Federation (FIP) has published two new handbooks to support pharmacists in providing 'much-needed' mental health services. The federation unveiled "Mental healthcare - A handbook for pharmacists" and "Knowledge and skills reference guide for professional development in mental health care" on Thursday July 7. The handbooks, developed in collaboration with an international group of experts, aim to support pharmacy practice, presenting the many potential mental health care actions that pharmacists can perform, from preventing mental illness and screening for signs to optimising medication and responding to mental health crises. The reference guide is intended to accompany the handbook and defines the knowledge and skills that pharmacists need to acquire to provide such services.

The Royal Pharmaceutical Society (RPS) on Wednesday (14 February) launched consultations on two new pioneer curricula defining the clinical capabilities expected of entry-level advanced pharmacists practising in critical care and mental health. The advanced pharmacist critical care curriculum and the advanced pharmacist mental health curriculum are supplementary to the RPS core advanced curriculum. Interested stakeholders are invited to provide feedback on the content of the curricula, their feasibility in terms of delivery, their relevance to all countries, and how these may impact different social groups. Both consultations will be open until Tuesday 12 March, and members and non-members of RPS can submit their comments via the online form or the word document.

The Royal Pharmaceutical Society (RPS) has released findings from its fifth annual workforce wellbeing survey, which was conducted in collaboration with the profession's charity, Pharmacist Support. Exposing the mental health challenges faced by pharmacists, the survey revealed a troubling statistic: 86 per cent of pharmacists are at a high risk of burnout. Inadequate staffing was the main factor contributing to burnout, followed by lack of work-life balance, insufficient protected learning time, absence of colleague or senior support, and long working hours. While pharmacies are encouraged to provide more clinical services, more than 60 per cent of pharmacists surveyed reported that they were not being offered "sufficient protected learning time" to focus on their professional development and learning needs. The survey also exposed a distressing trend of workplace abuse, with over 40 per cent of pharmacists reporting verbal abuse from the public, and 25 per cent from colleagues or managers.

The Royal Pharmaceutical Society (RPS) has called on employers, governments and NHS organisations to provide pharmacists with regular protected learning time (PLT) within working hours to develop their skills in clinical delivery, education, research and leadership. RPS workforce wellbeing survey showed an average 42 per cent of pharmacists were not given any PLT, a figure which rose to 55 per cent in community pharmacy. Most were unable to engage in professional development activities as part of their working day because of their responsibility to deliver frontline clinical services to patients. This means learning is often undertaken outside of working hours, increasing pressure on individuals and impacting their work/life balance. The survey showed that 48 per cent of respondents identified a lack of PLT as negatively affecting their mental health and wellbeing and that 88 per cent were at high risk of burnout. PLT improves the quality of patient care through professional practice and reflection, helping to develop insights, maintain and refine care standards and increase confidence. It facilitates continuous professional development (CPD), ensuring that skills and knowledge are up to date.

The Integrated Care Systems (ICSs) provide an opportunity to break the silo mentality in the health and care sector, National Pharmacy Association (NPA) chair Andrew Lane told MPs. While giving evidence to the Health and Social Care Select Committee on 6 December about the effectiveness of ICSs, Lane also poured cold water on newspaper reports that community pharmacists will be drafted in to break the NHS strike, as he reiterated the call for a "properly costed and funded environment." "We've been in different silos historically and ICSs are an opportunity to pull all systems together for the benefit of patients," he told committee members. Lane pointed to dementia-trained pharmacy delivery drivers and the Discharge Medicines Service as instances where the influence of community pharmacy already stretches beyond primary care into hospitals and social care. "We've seen pharmacists prescribe and get UTIs off doctors' desks, so we are starting to release capacity [in the system] and we're on that clinical journey. We welcome that, but it has to be with the right level of funding," he added.

The Royal Pharmaceutical Society (RPS) and Pharmacy Declares are inviting pharmacy teams from around the world to sign up and commit to taking "bold action" on climate change as mentioned in a climate change charter which was published on Monday (June 13). The charter asks pharmacy teams to commit to understanding how human health and the systems which underpin it are "reliant on the state of our natural environment" and actively explore ways to make pharmacy practice and medicine use more sustainable. It also asks to collaborate and share best practice to improve sustainability in pharmacy and healthcare; demonstrate leadership on sustainability or being a champion for sustainability at work; and assist patients to optimise their medicine use to increase both health outcomes and environmental sustainability. The individuals can also commit to a personal action on climate change of their own choosing. The Charter is being supported by a strong coalition of organisations from across pharmacy including the Centre for Postgraduate Pharmacy Education, the Clinical Pharmacy Association, College of Mental Health Pharmacy and Guild of Healthcare Pharmacists.

NHS England's decision to forgo commissioning puberty suppressing hormones (PSH) for children and young people, citing insufficient evidence of their safety and clinical effectiveness, follows a comprehensive review conducted by the National Institute for Health and Care Excellence (NICE) in 2020. The clinical report underscores that "PSH treatment options will not be part of routine commissioning" for people under the age of 18 in England grappling with gender incongruence or dysphoria. The NHS England review analysed nine observational studies on Gonadotrophin Releasing Hormone Analogues (GnRHa) and found no statistically significant difference in gender dysphoria, mental health, body image, and psychosocial functioning among children and adolescents treated with GnRHa. Duncan Rudkin, chief executive of the General Pharmaceutical Council (GPhC), acknowledged the challenges faced by pharmacy professionals regarding prescriptions for puberty suppressing hormones, stating:

Pharmacy professionals to be included as key stakeholders in the implementation, delivery and evaluation of a wide range of genomic services, said the Royal Pharmaceutical Society (RPS). RPS's statement has been developed in collaboration with pharmacy organisations who have co-badged the report, such as the British Oncology Pharmacy Association, the UK Clinical Pharmacy Association, Association of Pharmacy Technicians and the College of Mental Health Pharmacy. It looks at current and future roles for pharmacy professionals in genomic medicine across many aspects of practice such as person-centred care and collaboration, professional practice, education, leadership, management and research. Pharmacists and pharmacy technicians in the UK have already established roles in the application of genomic medicine in some areas of practice, such as antimicrobial stewardship and infectious diseases, and the management of certain genetic conditions, such as cystic fibrosis. The society believes, the current role of pharmacy professionals in genomics can be expanded upon in the future to both lead and support many relevant aspects of genomic implementation. These are described across all healthcare sectors, within the Genome UK strategy produced by the UK Government, and within the implementation plans published in England, Scotland and Wales. Lead for Pharmacogenomics at RPS Sophie Harding said: "Pharmacy professionals are the gatekeepers of medication safety and efficacy across all areas of healthcare. They are skilled at interpreting complex scientific data and use evidence-based medicine to maximise the benefits of treatments for patients, whilst supporting shared decision-making with patients and the multidisciplinary team.